Financial Performance - The company's operating revenue for Q1 2023 reached ¥3,085,538,744.52, representing a 46.83% increase compared to ¥2,101,428,825.31 in the same period last year[17] - The total operating revenue for the first quarter of 2023 was RMB 3,085,538,744.52, an increase of 46.9% compared to RMB 2,101,428,825.31 in the same period last year[23] - Net profit attributable to shareholders for Q1 2023 was ¥239,309,926.36, up 57.35% from ¥152,091,656.06 year-over-year[32] - The net profit for the first quarter of 2023 was RMB 239,308,006.44, representing a 57.4% increase from RMB 152,091,656.06 in the same quarter of the previous year[24] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥233,618,771.10, reflecting a 71.90% increase from ¥135,904,532.94 in the previous year[32] Operating Costs and Expenses - The operating cost for Q1 2023 was ¥2,222,844,353.53, which is a 44.80% increase from ¥1,535,066,594.09 year-on-year, primarily due to the increase in operating revenue[17] - The total operating costs for the first quarter of 2023 were RMB 2,727,579,280.84, up 40.8% from RMB 1,936,664,962.32 in the previous year[24] - R&D expenses increased by 42.14% to ¥202,240,389.62 from ¥142,277,701.47 in the previous year, indicating a significant investment in new product development[17] - Research and development expenses for the first quarter of 2023 amounted to RMB 202,240,389.62, which is a 42.2% increase compared to RMB 142,277,701.47 in the previous year[24] Assets and Liabilities - The company's total assets as of the end of Q1 2023 were ¥12,683,652,944.07, up from ¥12,016,599,023.18 at the beginning of the year[9] - The total liabilities as of the end of the first quarter of 2023 were RMB 6,924,825,286.56, an increase from RMB 6,497,373,460.37 at the end of the previous year[23] - The total liabilities increased, with short-term borrowings rising to ¥673,953,477.78 from ¥562,811,090.10, reflecting increased financing needs[9] - The company's cash and cash equivalents decreased, with other current assets dropping to ¥102,317,739.61 from ¥139,621,228.25, indicating tighter liquidity[9] Cash Flow - The net cash flow from operating activities was ¥222,944,074.02, which is a 29.85% increase compared to ¥171,696,287.82 in the same period last year[32] - Operating cash inflow for the current period reached $2,181,544,246.36, a significant increase from $1,512,778,824.01 in the previous period, reflecting a growth of approximately 44.2%[50] - Cash received from sales of goods and services was $1,996,810,525.10, compared to $1,369,763,853.07, reflecting an increase of about 46.0%[50] - Cash outflow from investing activities was $199,419,106.10, compared to $221,739,313.74 in the previous period, showing a decrease of approximately 10.1%[51] - Net cash flow from financing activities decreased by 71.66% to ¥102,872,647.96 from ¥363,036,069.47 in the previous year, primarily due to increased loan repayments[37] Shareholder Equity - The total equity attributable to shareholders of the parent company was RMB 5,751,482,414.06, up from RMB 5,511,878,399.44 in the previous year[23] - Shareholders' equity attributable to the parent company was ¥5,751,482,414.06, up 4.35% from ¥5,511,878,399.44 at the end of the previous year[32] - The weighted average return on equity for Q1 2023 was 4.24%, an increase from 2.96% in the same period last year[32] Other Information - The company reported a net loss from investment of ¥7,432,195.11, a decline of 178.55% compared to a profit of ¥9,461,798.73 in the previous year[17] - The fair value change income was ¥4,192,034.14, a significant recovery from a loss of ¥4,041,823.60 in the same period last year, indicating improved market conditions[17] - The company has not disclosed any new product developments or market expansion strategies in the provided data[26] - The first quarter report was not audited, indicating that the figures are preliminary and subject to change[27]
普洛药业(000739) - 2023 Q1 - 季度财报